ArticleHepatology international2014
Upregulation of CD147 protects hepatocellular carcinoma cell from apoptosis through glycolytic switch via HIF-1 and MCT-4 under hypoxia.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Lactate and lactylation: metabolic architects of tumor progression and metastasis.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.International journal of cancer · 2026Review
- Beyond the convergence of metabolic reprogramming in primary liver cancer: a comprehensive review on energy and lipids metabolism.Frontiers in cell and developmental biology · 2026Review
- Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview.International journal of molecular sciences · 2024Review
- SETDB1-mediated CD147-K71 di-methylation promotes cell apoptosis in non-small cell lung cancer.Genes & diseases · 2024Article
- CD147: an integral and potential molecule to abrogate hallmarks of cancer.Frontiers in oncology · 2023Review
- Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma.Frontiers in oncology · 2022Review
- Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment.Frontiers in oncology · 2022Review
- HIFZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Interaction of CD147 and human epididymis protein 4 promotes invasion and metastasis of ovarian cancer.Journal of Cancer · 2021Article
- Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review.Frontiers in cellular and infection microbiology · 2021Review
- Review
- Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology.BioMed research international · 2020Article
- Enhanced glycolytic metabolism supports transmigration of brain-infiltrating macrophages in multiple sclerosis.The Journal of clinical investigation · 2019Article
- Article
- CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHypoxia is a vital factor in supporting and directing hepatocellular carcinoma (HCC) progression. HIF-1 transactivates target genes involved in metabolic reprogramming and antiapoptosis under hypoxia. However, key molecules involved in HCC hypoxia adaptation remain to be characterized. The aim of this study was to investigate the mechanism and biological function of CD147 on HCC cells resistant to apoptosis under hypoxic conditions.
methodsApoptotic rates of hypoxia-treated HCC cells were investigated by flow cytometer, and the expression levels of CD147, HIF-1α, MCT-1 and MCT-4 were assayed by immune blot. The in vitro glycolytic capacity was investigated in SMMC-7721 cells and 7721-shCD147 cells (CD147 is stably knocked down). Immunohistochemical staining of CD147, Glut-1, MCT-1, MCT-4, LAT-1 and CD98 was detected in tumor tissues from a xenograft model. Immunofluorescence double-labeled staining allowed further exploration of the expression levels and localizations of CD147, MCT-1 and MCT-4.
resultsUpregulation of CD147 under hypoxia correlates with higher viability of HCC cells compared with that in HSC cells. Silencing of CD147 significantly inhibited the glycolytic rate and induced apoptosis in SMMC-7721 cells. The expression level of lactate secretion transporter MCT-1/MCT-4 is dependent on CD147, while the expression level of Glut-1, LAT-1 and CD98 remained unchanged. Particularly, MCT-4 is demonstrated to be essential for the membranal localization of CD147.
conclusionsWith the above findings, we conclude that within the HCC hypoxic microenvironment, upregulation of CD147 and MCT-4 involved in glycolytic reprogramming is decisively important for the viability of HCC cells under hypoxia adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.